|Title:||Il-6-Encoding Tumor Antigen Generates Potent Cancer Immunotherapy through Antigen Processing and Anti-Apoptotic Pathways||Authors:||HSIEH, CHANG-YAO
|Keywords:||HUMAN-PAPILLOMAVIRUS TYPE-16;DNA VACCINE POTENCY;SERINE- PROTEASE INHIBITOR-6;IMMUNOLOGICAL RESPONSES;DENDRITIC CELLS;T-LYMPHOCYTES||Issue Date:||2007||Journal Volume:||v.15||Journal Issue:||n.10||Start page/Pages:||1890-1897||Source:||MOLECULAR THERAPY||Abstract:||
A naked DNA vaccine delivered by gene gun into antigen- presenting cells (APCs) has emerged as an attractive strategy for antigen-specific cancer immunotherapy. However, APCs have a limited lifespan, hindering their long -term ability to prime antigen-specific T cells. Furthermore, the potency of DNA vaccines is limited by their inability to process and present antigens. Interleukin-6 (IL-6) could play a role in immunity and cell apoptosis. We explored how the DNA vaccine encodes IL-6 to a model tumor antigen, human papilloma virus type-16 (HPV-16) E7. Mice vaccinated with IL-6/E7 DNA exhibited dramatic increases in E7-specific T- cell immunities , anti-E7 antibody responses, and impressive anti-tumor effects against E7 -expressing tumors. The in vitro results revealed that IL-6 enhances DNA vaccine potency through the major histocompatibility complex class I pathway via direct and cross-priming effects. In addition, the delivery of IL-6/E7 DNA prolonged the survival of transduced dendritic cells (DCs) in vivo. Our results indicated that the IL-6/E7 DNA vaccine combined the mechanisms of enhancing antigen processing and presentation with prolonging the survival of DCs. Using IL-6 represents an innovative approach to enhancing DNA vaccine potency and holds promise for cancer prevention and immunotherapy.
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.